期刊
FRONTIERS IN BIOSCIENCE-LANDMARK
卷 26, 期 2, 页码 206-237出版社
BIOSCIENCE RESEARCH INST-BRI
DOI: 10.2741/4892
关键词
NAFLD; NASH; Therapy; Insulin Sensitizers; Antioxidants; Statins; Incretins; Cytokines; Bariatric Surgery; Gut Microbiome; Review
资金
- ICMR [59/05/2019/ONLINE/BMS/TRM]
- SERB [SRG/2019/000398]
- Wellcome Trust/DBT India Alliance Fellowship [IA/I/16/2/502691]
NAFLD and NASH are significant diseases related to metabolic syndrome, with slow progress in the therapeutic field, urging the need to identify appropriate treatment methods.
Non-alcoholic fatty liver disease (NAFLD) is one the fastest emerging manifestations of the metabolic syndrome worldwide. Non-alcoholic steatohepatitis (NASH), the progressive form of NAFLD, may culminate into cirrhosis and hepatocellular cancer (HCC) and is presently a leading cause of liver transplant. Although a steady progress is seen in understanding of the disease epidemiology, pathogenesis and identifying therapeutic targets, the slowest advancement is seen in the therapeutic field. Currently, there is no FDA approved therapy for this disease and appropriate therapeutic targets are urgently warranted. In this review we discuss the role of lifestyle intervention, pharmacological agents, surgical approaches, and gut microbiome, with regard to therapy for NASH. In particular, we focus the role of insulin sensitizers, thyroid hormone mimetics, antioxidants, cholesterol lowering drugs, incretins and cytokines as therapeutic targets for NASH. We highlight these targets aiming to optimize the future for NASH therapy.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据